1387 related articles for article (PubMed ID: 6747294)
1. Inhibition of immune precipitation by complement.
Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
[TBL] [Abstract][Full Text] [Related]
2. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
Ziccardi RJ
J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
[TBL] [Abstract][Full Text] [Related]
3. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
Takata Y; Tamura N; Fujita T
J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of immune precipitation by complement.
Schifferli JA; Bartolotti SR; Peters DK
Clin Exp Immunol; 1980 Nov; 42(2):387-94. PubMed ID: 6781802
[TBL] [Abstract][Full Text] [Related]
5. Prevention of immune precipitation by purified components of the alternative pathway.
Naama JK; Holme E; Hamilton E; Whaley K
Clin Exp Immunol; 1985 Apr; 60(1):169-77. PubMed ID: 3159522
[TBL] [Abstract][Full Text] [Related]
6. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
7. The influence of classical pathway components during alternative pathway--modulated immune complex aggregation: the role of C1 INH.
Gronski P; Bodenbender L; Kanzy EJ; Seiler FR
Behring Inst Mitt; 1984 Nov; (76):29-41. PubMed ID: 6335396
[TBL] [Abstract][Full Text] [Related]
8. The role of C1, C1-inactivator and C4 in modulating immune precipitation.
Schifferli JA; Steiger G; Schapira M
Clin Exp Immunol; 1985 Jun; 60(3):605-12. PubMed ID: 4017288
[TBL] [Abstract][Full Text] [Related]
9. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
Corvetta A; Spaeth PJ; Ghirelli PA; Orecchioni F; Buetler R; Montroni M; Nydegger UE
Diagn Immunol; 1983; 1(4):315-23. PubMed ID: 6333960
[TBL] [Abstract][Full Text] [Related]
10. Prevention of immune precipitation by purified classical pathway complement components.
Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
[TBL] [Abstract][Full Text] [Related]
11. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
Kievits F; Kijlstra A
Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
[TBL] [Abstract][Full Text] [Related]
13. Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a).
Schifferli JA; Steiger G; Paccaud JP
Clin Exp Immunol; 1986 May; 64(2):407-14. PubMed ID: 3488858
[TBL] [Abstract][Full Text] [Related]
14. Control of immune complexes by the classical pathway.
Whaley K; Ahmed AE
Behring Inst Mitt; 1989 Jul; (84):111-20. PubMed ID: 2529842
[TBL] [Abstract][Full Text] [Related]
15. Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways.
Schifferli JA; Woo P; Peters DK
Clin Exp Immunol; 1982 Mar; 47(3):555-62. PubMed ID: 6979442
[TBL] [Abstract][Full Text] [Related]
16. Humoral immunostimulation. IV. Role of complement.
Shearer WT; Atkinson JP; Frank MM; Parker CW
J Exp Med; 1975 Apr; 141(4):736-52. PubMed ID: 1168690
[TBL] [Abstract][Full Text] [Related]
17. Tetanus toxoid-anti-tetanus toxoid complexes: a potential model to study the complement transport system for immune complex in humans.
Paccaud JP; Steiger G; Sjöholm AG; Spaeth PJ; Schifferli JA
Clin Exp Immunol; 1987 Aug; 69(2):468-76. PubMed ID: 2958199
[TBL] [Abstract][Full Text] [Related]
18. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.
Doekes G; van Es LA; Daha MR
Immunology; 1983 Jun; 49(2):215-22. PubMed ID: 6852866
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
20. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
